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Atrial ﬁbrillation (AF) is a common and frequently disabling chronic condition associated with signiﬁcant patient morbidity
and aﬀecting an increasing stratum of our ageing society. Direct costs related to atrial ﬁbrillation are comprised from direct
cost of medical therapy, catheter ablation, and related hospitalizations and imaging procedures, with indirect costs related to
complications of the primary therapeutic strategy, management of related conditions, as well as disability and loss in quality
of life related to AF. Over the last decade, catheter ablation became a promising alternative to rate and rhythm control among
symptomatic AF patients. The purpose of this paper is to describe the evidence on the ﬁnancial implications related to ablation
based on published data and authors’ experience.
1.Implicationsof AtrialFibrillation
Atrialﬁbrillation (AF)isthemost commonsustainedcardiac
arrhythmia [1]. It is responsible for most arrhythmia-
related hospitalizations and leads to the greatest length of
hospital stay associated with any disorder of the cardiac
rhythm [2]. While associated with increased mortality in
the aﬀected patients, atrial ﬁbrillation is thought to be
responsible for the majority of thromboembolic events,
many of these preventable [3]. Strokes reported with equal
frequency in patients with both paroxysmal and permanent
atrial ﬁbrillation have been more devastating and associated
with greater disability than embolic events related to other
cardiac disorders [4–6]. Patients with AF account for 15%
of all strokes and are at a signiﬁcantly increased risk of
death due to stroke and heart failure [7]. Of all patients
experiencing a stroke related to AF, 60% will be discharged
with a new disability while 20% will die [8]. While the
most apparent negative outcome of this arrhythmia, strokes
a r eb yf a rj u s tt h et i po ft h ei c e b e r g .P a t i e n t sw i t hA F
are prone to develop rapid poorly controlled heart rate
associated with signiﬁcant disability and development of
cardiomyopathy in some patients. These patients along with
those who have hypertrophic cardiomyopathy and other less
obvious etiology of diastolic dysfunction are at substantial
risk of developing congestive heart failure while in AF [9].
Recentevidencealsosuggestsgreatermortalitysimplyrelated
to faster heart rates in some patients [10]. A staggering
70%–80% of AF patients are admitted to hospital at some
point in the course of their disease. Finally, AF is a source
of disability for many younger members of the workforce
who feel out of control when their heart rate suddenly
becomes erratic. It may lead to frequent hospital visits
[11], inpatient and outpatient monitoring, imaging and
cardioversion procedures, and, of course, invasive therapies
ranging from cardiac pacing in patients with concomitant
dysfunction of the sinus node, to ablation of the AV node in
concert with permanent pacing or cardiac resynchronization
therapy and to the “curative” ablation of the cardiac tissues
thought to trigger and perpetuate AF.
2.SourcesofCostinAF
Multiple negative health outcomes in AF patients as well
as AF treatment strategies contribute to an ever-growing
tap drawn on the healthcare system and the society at
large. To make matters worse, AF is a disorder aﬀecting
preferentially older members of the society with greater
than 10% prevalence in those over the age of eighty [4].
This is a disastrous proposition in an aging society with2 Cardiology Research and Practice
exponentially increasing occurrence of this condition and
subsequently skyrocketing costs related to the associated
morbidity, disability, and treatment. A recent systematic
review of the cost of AF care revealed that the overall average
annual cost to support the system to manage one AF patient
is $7,226 with a range of estimated costs as high as just
over $10,000 [12]. While these costs are substantial, they
represent only about one quarter of the entire health system
costs for patients with AF. Two studies estimated the entire
system cost for all care for patients with AF to range between
$20,613 to $40,169. Hospitalizations are the most important
determination of total cost (58%) with the cost of a single
acute admission in Ontario with AF as a primary diagnosis
of $24,096 [13]. Rhythm and rate control strategies targeting
disability related to AF have seen little evolution over the
years, and no radically new agents have come to market in
decades. Multiple comparisons of these strategies have come
in short of ﬁnding a winner, and both approaches have had
signiﬁcant clinical limitations [14–16].
3.CostContainmentStrategies
A number of studies have looked at the potential cost
containment strategies. Of these, the most obvious is greater
attention to anticoagulation therapy in patients suﬀering
from AF. The bulk of current cost of AF care is related
to thromboembolism, yet currently as few as 10%–20% of
the AF patients are treated with appropriate prophylaxis
strategies [5]. Those who do take oral anticoagulants spend
much of their time taking subtherapeutic doses of the
medication placing them at risk of stroke, while others
take supertherapeutic doses and run a signiﬁcant risk of
bleeding given a very narrow therapeutic range of warfarin.
Multiple new medications targeted to prevent stroke in AF
patients are becoming available, but while easier to use,
these may have their own risks related to lack of reversibility
and may carry a substantial upfront cost [17]. A new
antiarrhythmic medication, dronedarone, available to the
clinicians in Canada for just over a year had shown promise
of lesser risk of toxicity and uniquely was shown to reduce
morbidity and mortality in AF patients, but has done so
despite being no more eﬀective at controlling the actual
rhythm disorder than the other drugs. The impact this
strategy will have on the cost of care in AF remains to be
determined.
Another such strategy has to do with ablation. First
promise for a potential cure for AF came in 1998 when
it became apparent that ectopic atrial activity originating
in the pulmonary veins may be responsible for initiation
of AF and could be targeted with radiofrequency energy
[18]. The ﬁeld of targeting AF triggers had seen substantial
progress since this discovery with multiple tools coming to
market over the last decade in an eﬀort to improve the safety
and eﬃcacy of these procedures. Most of these strategies
involved delivering various types of energy just proximal to
the insertion of the pulmonary veins into the left atrium
using conventional, irrigated tip, and circular- and balloon-
shaped catheters. Another strategy that was ﬁrst described
in 2004 and had seen much technological attention has
been that of targeting tissues thought to perpetuate AF or
presenting so-called AF substrate [19]. These latter eﬀorts
have focused on elimination of the viable atrial myocardium
displaying particularly disorganized activity during AF or
delivering energy over autonomic nerve ganglia thought to
initiate and perpetuate the arrhythmia.
These approaches have shown promise in a multitude
of individual center and multicenter randomized trials uni-
formly showing clinical beneﬁt of ablation over antiarrhyth-
mic drug therapy with respect to sinus rhythm maintenance,
quality of life, and arrhythmia, related hospitalizations in at
least some populations [20–22].
Unfortunately, in this rapidly evolving ﬁeld most studies
have focused on short-term comparisons between ablation
and medical therapy as well as on the assessment of the
relative eﬃcacy of ablation strategies and tools. While the
literature is unanimous in praising ablation as winner with
respect to control of symptomatic arrhythmia over 6–12
months, until recently little has been published about the
long-term eﬃcacy of ablation and even less about its eﬀect
on mortality and embolism. Initial reports of AF ablation
suggestedgreaterthan90%freedomfromarrhythmia among
treated patients. Now a decade later many are publishing
results suggesting much more modest upfront beneﬁts with
ad i ﬃcult to ignore success attrition rate. While long term
success rates varied drastically in these publications from
9% very late recurrence rate reported by Shah et al. [23]
to 92% recurrence rate reported by Katritsis et al. [24],
most investigators agreed that AF ablation does not impart
cure of this condition in a signiﬁcant number of patients.
Incidentally, our ﬁndings of 42% recurrence following
pulmonary vein antrum isolation with 30% likelihood of
further arrhythmia in patientsthoughtofas“cured”oneyear
following the procedure represent a medium late recurrence
rate compared to these publications, are in line with the
recent report by Bertagliaet al.[25],anddemonstratealower
annual recurrence rate following the ﬁrst year compared to
t h er e p o r tb yT z o ue ta l .[ 26]. Moreover, patients suﬀering
from further AF are subjected to multiple repeat procedures
further contributing to the growing cost to healthcare.
Our well-characterized cohort of patients for the ﬁrst time
illustrated ever-diminishing return on this investment with
50% success of the second and 25% success of the third
ablation.
4.AblationversusMedicalTherapy:
CostPerspective
Several projections of cost of care of an AF patient have
been published in an attempt to estimate the relative cost of
ablation and contrast it to the cost of medical therapy over
time. A study directly comparing the costs of ablation and
medical therapy in the Canadian healthcare environment
has been published [27]. Costs related to medical therapy
in the analysis included the cost of anticoagulation, rate and
rhythm control medications, noninvasive testing, physician
followup visits, and hospital admissions, as well as the
cost of complications related to this management strategy.
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the cost of the ablation tools (electroanatomic mapping
or intracardiac echocardiography-guided pulmonary vein
ablation),hospital and physician billings, and costsrelated to
periproceduralmedicalcareandcomplications.Costsrelated
to these various elements were obtained from the Canadian
Registry of Atrial Fibrillation (CARAF), government-fee
schedules, and published data. Sensitivity analyses looking at
a range of initial success rates (50%–75%) and late attrition
rates (1%–5%), prevalence of congestive heart failure (20%–
6 0 % )a sw e l la sd i s c o u n t i n gv a r y i n gf r o m3 %t o5 %p e r
year were performed. In this study, the cost of catheter
ablation strategy ranged from ∼US$14,000 to US$18,000.
It was assumed that patients who required anticoagulation
prior to ablation would continue on this therapy following
the procedure with an annual average followup cost of
US$1400toUS$1800amongtheablatedpatients.Theannual
cost of medical therapy ranged from US$3,600 to US$4300.
The latter estimate was supported by the ﬁndings from
the FRACTAL registry which prospectively collected clinical
and cost data for 973 patients with atrial ﬁbrillation [28].
The study projected costs of ongoing medical therapy and
catheter ablation to equalize at 3.2 to 8.4 years of followup in
this study but did not take into account development of the
novel antiarrhythmic and thromboprophylactic strategies
not available at the time of the publication.
A number of AF cost estimates have been published
internationally. Treatment costs associated with followup
of AF patients including hospital admissions, emergency
room visits, and testing and followup with cardiologists,
internists, and family physicians were analyzed in France
[29].This analysis stratiﬁed patientsaccordingtotherapeutic
strategy—rate or rhythm control—as well as according to
concomitantcongestive heart failure symptoms. The authors
estimated the average total 5-year cost of AF at 16,539 Euro.
In a study from Bordeaux, 118 patients 52 ± 18 years of age
withsymptomatic drugrefractory paroxysmalAFunderwent
1–4 pulmonary vein isolation procedures per patient [30].
All patients previously failed at least 2 antiarrhythmic
drugs, with close to 80% having failed amiodarone. During
a followup period of 32 ± 15 weeks, 72% of them were
free of AF without the use of antiarrhythmic drugs. The
cost of care was estimated in 2001 Euro. Procedural costs
and costs related to hospitalization were obtained from
hospital billing data. The cost of medical therapy was based
on review of 20 consecutive patients and accounted for
antiarrhythmic drugs used, frequency of symptoms prior to
ablation, frequency of visits to the emergency room, doctor’s
oﬃce visits, and hospital admissions. All future costs were
estimated using 5% discounting/year. It was assumed that
patients were hospitalized for 5 days around the time of
ablation. Neither complex mapping systems nor intracardiac
echocardiography were used or accounted for. Furthermore,
it was assumed that patients were treated with a ﬁxed
antiarrhythmic routine for 12 months prior to ablation. The
projected annual cost of medical therapy was estimated at
1,590 Euros. The upfront cost of ablation was estimated at
4,715 Euros. Assuming that ablation was successful in 28%
ofall patients, the costofongoing care inthe ablatedpatients
was estimated at 445 Euros per year. As a result, the costs of
medical therapy and ablation crossed over between four and
ﬁve years. Since no complications occurred in the ablated
patients in this study, these were not accounted for in the
analysis. Furthermore, followup costs were accrued only for
patients failing AF ablation with no additional cost assigned
to followup of the successfully ablated patients.
In an in-depth look at the cost of AF ablation among
Medicarepatientsfollowedforayearafterablation,Kimetal.
found the cost of successful ablation at US$16,049 ± 12,536
versus US$19,997 ± 13,958 for failed ablation. Ablation was
successful in 51% of the patients in his cohort, similar to our
ﬁndings [31].
Four papers attempted to perform a cost-beneﬁt analysis
of AF ablation with that of medical therapy. In the ﬁrst
of these studies, a Markov decision analysis model looking
at 55- and 65-year-old cohorts of patients at low and
moderate risk of stroke was created by the investigators [32].
Complications and costs related to AF, medical therapy, and
catheter ablation were accounted for. The model assumed
that amiodarone would be used for rhythm control and
a combination of digoxin and atenolol—for rate control.
Eighty percent eﬃcacy of AF ablation was assumed with
30% redo rate during the ﬁrst year and 2% per year late
success attrition rate. It was further assumed that as many as
38% of the patients on rate control would convert to sinus
rhythm with annual AF relapse rate of 5%. Moderate risk
of stroke was deﬁned as having one risk factor, including
diabetes,hypertension, coronaryartery disease,orcongestive
heart failure. Patients at low risk of stroke were assumed to
have no such risk factors. For the purpose of the model,
patients at moderate risk of stroke were anticoagulated,
whereas those at low risk could be on warfarin or aspirin.
The model incorporated annual stroke risk of 2.3% and
1.1% for patients treated with aspirin and 1.3% and 0.7%
for those on warfarin at moderate and low risk for stroke,
respectively. A relative stroke risk of 1.4% per decade was
accounted for. Age-adjusted mortality based on life tables
and mortality reductionsattributabletoaspirin and warfarin
were accounted for. All health care costs were calculated in
2004US dollars using 3% discounting per year. Costs were
estimated based on Medicare reimbursement rates, hospital
accounting information, published literature, and the Red
Book for wholesale drug costs. Catheter ablation appeared
to be most cost-eﬀectivein youngerpatientsatmoderate risk
of stroke at $28,700/QALY gained. It was somewhat less cost
eﬀectiveinthe oldermoderate risk patientsat$51,800/QALY
gained and least cost-eﬀective among the younger patients
at low risk of stroke at $98,900/QALY gained. Unfortunately,
since no evidence has been presented to date on the eﬃcacy
of ablation for prevention of thromboembolic events, the
ﬁndings of this study are conditional on such evidence
coming to light in the years to come.
Eckard et al. developed a decision-analytic model to
estimate costs, health outcomes and incremental cost-
eﬀectiveness of RFA compared to AAD treatment for AF for
a lifetime time horizon [33].The authorsused a decisiontree
for the initial year in which the RFA procedure is assumed to
take place, and a long-term Markov structure for subsequent
years. The authors factored in the potential for a second4 Cardiology Research and Practice
ablation within a year of the ﬁrst procedure in patients
still suﬀering from AF. They assumed 70%–80% ablation
success within the ﬁrst year with 1.4 ablations per patient
requiredtomaintainrhythm basedonSwedishdata.Thecost
of ablation was estimated at around US$12,000, including
the cost of 3-4 days in hospital, all diagnostic examinations
necessary as well as the cost of disposables. Annual cost of
AF therapy was estimated at US$2000. In order to estimate
QALY weights for diﬀerent health states, age-adjusted QALY
weights based on a Swedish general population were applied
for patients in the controlled AF state and used as reference
points. A decrement of 0.1 for uncontrolled AF and 0.25 for
stroke was applied to the baseline utility in the controlled
AF state. With annual success attrition rates of 5%, 10%,
and 15% used in the sensitivity analysis, the relative cost
of ablation was estimated up to US$58000 per QALY
without assuming stroke prevention related to the ablation
strategy.
A similar analysis in the United Kingdom suggested
incremental cost eﬀectiveness of ablation at US$16,000 per
QALY in 2008 dollars. The authors of this paper assumed
freedom from AF at 84% at one year with 2%–4%/year rate
of success attrition over time resulting in their estimates
favouring ablation over the other published economic analy-
ses. Further sensitivity analyses found the estimate to depend
signiﬁcantly both on the relative QOL estimate associated
with sinus rhythm and on the prognostic implications of
being in rhythm [34].
Finally in a more recent paper, Reynolds and his group
published a Markov model cost-eﬀectiveness analysis of
ablation versusantiarrhythmic therapy in a simulated cohort
of patients with paroxysmal drug refractory AF projected
over 5 years. The authors assumed 60% success of the
ablation approach with a 25% rate of repeat ablation.
Utilities for QOL assessment were derived from real-life
data, using the FRACTAL registry for the medically treated
patients using SF-12 and patients ablated at the authors’
institution as well as those enrolled in the A4 trial for
derivation of the scores in this cohort based on the SF-
36 questionnaire. In the base scenario, the incremental cost
per QALY among ablated patients was US$47,333 with cost
neutrality achieved at ∼10 years [35].
This latter ﬁnding corresponds to the extreme variation
in the model originally presented by Khaykin et al, where
assuming actual clinical outcomes and costs incurred in
the care of over 600AF patients since 2004, the costs
of ablation and medical therapy would be expected to
reach parity at 6–9 years for patients with paroxysmal
AF and at 8–15 years for patients with nonparoxysmal
AF. Unfortunately, there is little well-reported data on
AF followup greater than 5 years postablation, and sig-
niﬁcant advances in technology and medical therapy are
typically seen over such an extended period with signiﬁcant
premium associated with new treatment modalities and
little concurrent data on any associated clinical beneﬁt
over the standard of care. In this environment, exact
relative costs of ablation and medical therapy remain elusive
leaving us with reasonably well-grounded assumptions at
best.
5.Global Perspective
While there is accumulating data from multiple geographies
that ablation is both clinically superior and is economically
feasible in certain populations, it may not be available
globally. Furthermore, despite the advent of international
practice guidelines, the care of AF patients, thresholds for
application of therapies with an expensive upfront price
tag such as ablation may vary dramatically from country
to country and between population strata within any given
geography.Agoodillustrationofthisprincipleisan in-depth
analysis looking at the direct cost of AF care across several
European countries for a prespeciﬁed patient (female aged
<65 years with ﬁrst-detected AF and no comorbidities at
baseline) where costs varied from about US$1000 per year
to US$2200 [36]. That said, reassuringly, the estimates of
cost and cost eﬀectiveness of ablation have been within close
range ofeach otherin Canada, the UnitedStates, and Europe
using a variety of assumptions taken and sensitivity analysis
performed, generally speaking supporting the claim of cost
eﬀectiveness of ablation.
6.FutureConsiderations
Several developments may impact our understanding of the
cost eﬀectiveness of AF ablation in the next decade. First
and foremost, the techniques of AF ablation are constantly
evolving and we have seen an unprecedented inﬂux of new
AF ablation technologies. While all published studies are
based on the success of standard point-by-point AF ablation,
and most long-term studies followed patients ablated using
a solid tip catheter, the broader adoption of irrigated tip
catheters in the last few years and new ablation technologies
may change the landscape of AF ablation by substantially
improving outcomes and reducing resources and operator
training necessary to achieve success. Whether this would
translate into improved economics of AF ablation will
depend to a large extent on the incremental cost of these
technologies in relation to incremental success or reduction
i nt h er a t eo fp r o c e d u r a lc o m p l i c a t i o n s .
New antithrombotic agents such as dabigatran may sub-
stantially reduce the cost related to anticoagulation man-
agement and may usher in an era of intermittent oral
anticoagulation targeted to the time the patients actually
spend in AF. This may substantially impact the cost of
medical therapy, making it more attractive but would also
improve the cost of the ablation strategy in patients who
would no longer require preoperative bridging of their
anticoagulation and will aﬀect the cost of ongoing therapy
in patients following ablation.
Similarconsiderationsmayapplytothenew antiarrhyth-
mic agents which, like dronedarone, may be less likely to
cause long-term complications associated with this group of
drugsinthepastandthereforewouldbeexpectedtoimprove
the cost of medical therapy.
Finally, a large multicenter international trial, CABANA,
will help us get a better understanding of the relative risks
and beneﬁts of ablation and medical therapy using “hard”Cardiology Research and Practice 5
outcomes of death and stroke and will allow for a deﬁnitive
cost-eﬀectiveness analysis of AF ablation.
7.Conclusions
Atrial ﬁbrillation clearly remains a signiﬁcant medical dis-
order with far reaching social and economic implications.
Despite signiﬁcant advances in our understanding of this
condition, we are far from having developed a perfect
therapeutic strategy for AF. Several new agents that have
entered the market show promise for reduction of morbidity
and mortality related to this condition, while government
initiatives are coming into place to streamline care and avoid
preventable and costly negative health outcomes.
Several studies comparing ablation with medical therapy
support the claim of short-term beneﬁts related to the
invasive therapy among patients with paroxysmal AF. At
the same time, recent evidence suggests greater attrition of
success among ablated patients over the long run than used
inmost ofthese studies. Inthis climate, previously published
literaturesupporting long-termeconomicbeneﬁtof ablation
has to be critically reassessed, and new models based on real
life outcomes data need to be looked at to re-evaluate their
ﬁndings.
Finally, evolution of ablation technologies, antiarrhyth-
mic and antithrombotic agents, and large clinical trials
comparing the impact of ablation and medical therapy
on morbidity and mortality may radically change our
understanding of the economics of AF ablation in the next
few years.
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